New Alzheimers & Dementia Paper Highlights SpeechDxs Role in Advancing AI-Driven Tools for Earlier Alzheimers Detection and Risk Assessment

▤ Summary

This article highlights a new Alzheimer’s paper that positions SpeechDx as a key dataset for building AI-driven speech markers for earlier detection and risk assessment. It explains that the project collects longitudinal, multilingual speech data linked to biomarker-confirmed diagnoses and outcomes to help train and validate digital tools. The article also notes that the dataset has already been licensed by Siemens Healthineers and Callyope, signaling early commercial use. The core message is that better datasets can accelerate validated digital biomarkers and enable earlier, more personalized Alzheimer’s care.

▦ Linked Companies